Lyra Therapeutics (LYRA) CEO sells 1,702 shares to cover RSU taxes

Rhea-AI Filing Summary

Lyra Therapeutics President & CEO and Director Maria Palasis reported a small tax-related share sale. On 01/06/2026, she sold 1,702 shares of Lyra Therapeutics common stock at a price of $3.364 per share, coded as an "S" transaction.

According to the footnote, the sale was made to cover taxes upon the vesting of restricted stock units under a mandatory Rule 10b5-1 trading instruction adopted on January 1, 2025. After this sale, Palasis beneficially owned 1,096,733 shares of common stock, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Palasis Maria

(Last) (First) (Middle)

C/O LYRA THERAPEUTICS, INC.

480 ARSENAL WAY

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lyra Therapeutics, Inc. [ LYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S(1)		1,702	D	$3.364	1,096,733	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold to cover taxes upon the vesting of restricted stock units ("RSUs") pursuant to a mandatory Rule 10b5-1 trading instruction in the award agreement adopted by the Reporting Person on January 1, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

	/s/ Jason Cavalier, Attorney-in-Fact for Maria Palasis, Ph.D.	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did LYRA CEO Maria Palasis report?

Maria Palasis, President & CEO and Director of Lyra Therapeutics, Inc., reported selling 1,702 shares of common stock on 01/06/2026 at $3.364 per share, as shown in the Form 4.

Why did the LYRA CEO sell 1,702 shares of Lyra Therapeutics stock?

The footnote explains that the 1,702 shares were sold to cover taxes due upon the vesting of restricted stock units, under a mandatory Rule 10b5-1 trading instruction included in the award agreement adopted on January 1, 2025.

How many LYRA shares does Maria Palasis own after this Form 4 transaction?

Following the reported tax-related sale, Maria Palasis beneficially owned 1,096,733 shares of Lyra Therapeutics common stock, all reported as held directly.

What is the significance of the Rule 10b5-1 plan mentioned in the LYRA Form 4?

The transaction occurred under a mandatory Rule 10b5-1 trading instruction in the RSU award agreement, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) for pre-arranged trading.

What roles does Maria Palasis hold at Lyra Therapeutics (LYRA)?

Maria Palasis is identified in the filing as both a Director and an Officer of Lyra Therapeutics, Inc., serving as President & CEO.

Was this LYRA insider transaction a direct or indirect holding?

The Form 4 reports the common stock as held under direct ownership, with the ownership form marked as "D" and no indirect ownership entity specified.